Study on immune function of dendritic cells in patients with esophageal carcinoma

Shen-Ren Chen, Yi-Ping Luo, Jin-Kun Zhang, Wei Yang, Zhi-Chao Zhen, Lin-Xin Chen, Wei Zhang

AIM: To investigate the immune function of dendritic cells from both peripheral blood and operated tissues of esophageal carcinoma patients in order to find the relationship between the immune function of dendritic cells and the pathogenesis of esophageal carcinoma.

METHODS: The expression of CD83, CD80, and CD86 on the surface of dendritic cells cultured from the peripheral blood of patients was detected compared with that from healthy donors using flow cytometry. The ability of dendritic cells to induce T lymphocyte proliferation was evaluated by a liquid scintillation counter. The expression of CD80, CD86, CD83, and S-100 proteins was assessed in esophageal carcinoma tissues using immunohistochemical method.

RESULTS: Compared with those from healthy donors, dendritic cells cultured from the peripheral blood of patients expressed lower CD80 and CD86. Furthermore, the ability of dendritic cells in patients to induce T lymphocyte proliferation was significantly lower than that of the control group. Compared with the control group, the positive expression ratio and frequencies of CD80, CD86, and S-100 in esophageal carcinoma tissues were significantly down regulated. The expression of CD83 was up-regulated in the pericancerous tissues, but no expression was found in the cancerous nodules.

CONCLUSION: The impaired immune function and the decreased number of dendritic cells cause pathogenesis and progression of esophageal carcinoma.

INTRODUCTION

Esophageal carcinoma (EC) is one of the top ten frequently occurring malignant cancers, particularly common in China. Our
and confirmed by appropriate histological findings (hematoxylin and eosin staining). We took specimens from the esophageal carcinoma tissue (ECT), pericancerous tissue (PCT), and tissue far away from the esophageal carcinoma tissues about 8 cm as the normal esophageal tissue (NET). At the time of surgery, all patients were free from any other tumor therapy.

**Generation of DCs from peripheral blood mononuclear cells**
The DCs were generated from peripheral blood mononuclear cells (PBMC) according to the methods described by Zhu et al.[15-19]. The PBMC were collected from venous blood by Ficoll-Hypaque density-gradient centrifugation. After the PBMC were suspended in DCs culture medium (RPMI 1640 supplemented with 100 mL/L fetal calf serum, 50 U/mL penicillin, 2 mmol/L L-glutamine, and 50 µmol/L 2-mercaptoethanol), they were placed at 10 mL polystyrene cells (PBMNC) according to the methods described by Zhu et al.[15-19]. The PBMC were collected from venous blood by ficoll-hypaque density-gradient centrifugation. After the PBMC were suspended in DCs culture medium (RPMI 1640 supplemented with 100 mL/L fetal calf serum, 50 U/mL penicillin, 2 mmol/L L-glutamine, and 50 µmol/L 2-mercaptoethanol), they were placed at 10 mL polystyrene culture plates and stored at 37 °C for 2 h. After incubation, non-adherent cells were removed by gently pipetting with warm RPMI 1640. Adherent cells were supplied with DCs medium containing 800 U/mL of recombinant human GM-CSF and 500 U/mL of recombinant human IL-4, and cultured for 7 d at 37 °C under 50 mL/L CO₂. Cells were referred fresh medium containing 800 U/mL of GM-CSF and 500 U/mL of IL-4 every 2 d. After 7 d, the cultures developed an adherent monolayer and clusters of DCs colonies (Figure 1). The DCs yield was defined as the percentage of the obtained DCs numbers to the PBMNC numbers used as the source.

**Flow cytometric analysis**
After 7 d of culture, DCs were harvested, and their surface molecule expression was analyzed using FACS (Becton Dickinson Immunocytometry Systems, San Jose, CA). In each step of the staining, 5x10⁴ cells were stored with specific antibodies (Abs) for 30 min at 4 °C in 50 µL of PBS containing 20 mL/L of bovine serum albumin and 1 mL/L of sodium azide. For the staining of mouse monoclonal anti-human CD80, CD83, or CD86 (PharMingen, San Diego, CA), fluorescein isothiocyanate (FITC)-conjugated goat monoclonal anti-mouse IgG was used according to the procedure of indirect immunofluorescence staining. Isotypic Ab (purified mouse IgG) was substituted for specific Abs to obtain a negative control. After staining, all cells were fixed with 10 mL/L paraformaldehyde (Sigma), and analyzed with the FACStarP1 (Becton Dickinson) using a single argon laser. For the comparison of CD83 and costimulators, the mean fluorescence intensity of stained DCs (MFI) and that of controls (MFIc) was measured using a Consort 30 software program (Becton Dickinson). The degree of surface molecule expression was estimated as the ratio of MFIs to MFIc (MFIs/MFIc) and expressed as the net fluorescence intensity (NFI). All samples were assayed in duplicate.

**Immunohistochemical staining of CD80, CD86, and S100 proteins**
Immunohistochemical staining was performed. Rabbit anti-human monoclonal antibodies to CD80, CD86 and S100 proteins (PharMingen International) were used as primary antibodies (Ab1). The antigen-Ab1 complex was then incubated with biotinylated secondary antibody followed by horseradish peroxidase-avidin. Staining procedure was done according to the introduction of the agent box, SP method. A known sample from a patient with breast cancer was used as a positive control, and the staining for negative controls was followed the method described above, except for incubation with PBS instead of the primary antibody. Colorization was performed by diaminobenzidine (DAB)-hydrogen peroxide as a chromogen. **Immunohistochemical staining of CD83**
The staining of CD83 was performed with some modifications, according to a previously described method[19]. Formalin-fixed, paraffin-embedded specimens were washed three times in PBS and treated with pepsin (5 mg/mL in 0.01 mol/L HCl, Zhongshan, Beijing, China) for 20 min at 37 °C before staining for CD83. The specimens were then treated with normal goat serum for 20 min to block non-specific binding. The monoclonal antibody with appropriate dilution was then added. Tissue sections were treated with 0.3 mL/L methanol-hydrogen peroxide to inactivate endogenous peroxidase. The sections then were reincubated.

**Electron microscopy**
The nonadherent cells were aspirated, washed in PBS, pelleted, and fixed for 30 min in 30 g/L glutaraldehyde in 0.1 mol/L phosphate buffer (pH 7.35). After washing, the cells were postfixed for 1 h in 10 g/L buffered osmium tetroxide, washed once in phosphate buffer and 3 times in water, and stained with 5 mL/L aqueous uranyl acetate for 1 h. After dehydration through a series of ethanol dilutions, the cells were pelleted, and embedded in 1:1 Poly/Bed. Thin sections were cut with Diatome diamond knife, mounted 200 mesh nickel guides, and poststained with 50 mL/L methanolic uranyl acetate. Samples were viewed on a Philips 400 transmission electron microscope (Figure 2).

**Mixed lymphocyte reaction**
To evaluate the allostimulatory capacity of DCs, mixed lymphocyte reaction (MLR) was performed. To compare the function between DCs from EC patients (EC-DCs) and those from donors (N-DCs), allogeneic lymphocytes were obtained from the same healthy volunteer. The PBMNC were suspended in DC culture medium and incubated at 37 °C under 50 mL/L CO₂ for 1 h, non-adherent cells were gathered as T cells (TCs). After DCs were treated with 50 µg/mL of mitomyacin C for 45 min at 37 °C, they were suspended in DC medium and placed at 1x10²-2x10⁵/well on 96-well flat-bottom culture plates. The TCs were mixed with DCs at 2x10⁵/well and cultured for 96 h at 37 °C, 50 mL/L CO₂. During the last 16 h of incubation, pulse labeling was done with 2.0 µCi/well of [³H] thymidine (MSL, Beijing, China). Assays were performed in triplicate. On day 4, the cells were harvested, and the amounts of [³H] thymidine incorporated to responder cells were counted with a beta counter. The ratio of MLR was determined by the ratios of cpm between EC-DC and N-DC in the presence of the same reagents at a TCs/DCs ratio of 10 to 1.

**Figure 1** Typical appearance of DC cultures on 7 d.

**Figure 2** Transmission electron microscopy (×8000).

Chen SR et al. Immune function of dendritic cells in esophageal carcinoma 935
with biotinylated goat anti-mouse immunoglobulin at room temperature for 1 h. After a wash in PBS, sections were soaked in alkaline phosphatase-conjugated streptavidin, washed, and New Fuchsin was used as a chromogen. A known sample from patients with primary biliary cirrhosis was used as a positive control. The staining of negative controls was performed using PBS instead of primary antibody.

**Enumeration of positive staining cells** The numbers of CD80-, CD86-, S100-, and CD83-positive cells in the whole specimen were determined. The prevalence of CD80, CD86, and S100 protein-positive cells were shown as the ratio of a total 100 infiltrating cells. The prevalence of CD83 positive cells was shown as total numbers of cells/specimen.

**Statistical analysis**
The data were expressed as mean±SD. The statistical analyses were done by unpaired and paired t-tests, when indicated. Mann-Whitney’s U-test and the Wilcoxon rank-sum test were also used when unpaired and paired t-tests were not indicated, respectively. P-values less than 0.05 were considered to indicate statistical significance. Statistical calculations were performed using the SPSS 10.0 statistical program.

**RESULTS**

**Phenotypic analysis of DC**

After 7 d of culture under GM-CSF and IL-4, the cells from patients or volunteers exhibited DC morphology with veiled dendrites. Through the observation from transmission electron microscopy, the cell surface was irregular but lacked the discrete microvilli and ruffles (Figures 1, 2). The cells were free polysomes and ribosomes, and lysosomes were scanty. These results showed that the generated cells from both patients and donors were morphological and compatible with DCs. The expression of CD80 and CD86 in EC patients was weaker than that in volunteers, but no the expression of CD83 was not different between EC patients and volunteers (Table 1 and Figure 3). The yield of DCs was not different between patients and donors (5±3% vs 5±1%).

**Low mixed lymphocyte reaction in DCs generated from EC patients**

In MLRs, the degree of T cell proliferation from EC-DCs was significantly lower than that from N-DCs. The reduced allogeneic response from EC-DCs was confirmed with the comparison of the cpm at a TCs/DCs ratio of 10 to 1 with large numbers of subjects (P<0.01) (Table 1). Since the responders were identical in each series of the comparisons, the difference in T cells proliferation mainly depended on the DCs difference.

**Table 1** Antigen presentation and ability to induce T lymphocyte proliferation on DCs in peripheral blood from donors and EC patients (% mean±SD)

<table>
<thead>
<tr>
<th>Group</th>
<th>CD80</th>
<th>CD86</th>
<th>CD83</th>
<th>MLR (cpm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donor</td>
<td>61.41±7.47</td>
<td>37.28±6.75</td>
<td>5.18±1.59</td>
<td>20 000±3 000</td>
</tr>
<tr>
<td>Patient</td>
<td>41.76±7.35</td>
<td>29.68±7.32</td>
<td>4.44±1.17</td>
<td>10 000±2 000</td>
</tr>
</tbody>
</table>

*P<0.01 vs donor group.

**Lower expression of CD80 and CD86 in EC patients**
The expression of CD80 and CD86 could be detected in the nucleus and cytoplasm but not on the cell membrane for all the specimens. The expression of CD80 and CD86 in the nucleus was found randomly. The expression in the cytoplasm was located in the necrotic area and around with infiltrated lymphocytes (Figure 4A, B, C, D). The prevalence of positive expression of CD80 and CD86 was lower in ECT than that in NET (P<0.01), but there was no significant difference between PCT and NET (Table 2).

**Table 2** Positive staining of CD80, CD86, and S100 proteins in esophageal tissues

<table>
<thead>
<tr>
<th>Group</th>
<th>Tissue</th>
<th>n</th>
<th>Prevalence</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD80</td>
<td>ECT</td>
<td>30</td>
<td>8 (26.7%)</td>
<td>24.37±4.87</td>
</tr>
<tr>
<td>CD80</td>
<td>NET</td>
<td>30</td>
<td>18 (60%)</td>
<td>46.25±4.04</td>
</tr>
<tr>
<td>CD86</td>
<td>ECT</td>
<td>30</td>
<td>12 (40%)</td>
<td>20.37±4.89</td>
</tr>
<tr>
<td>CD86</td>
<td>NET</td>
<td>30</td>
<td>13 (43.3%)</td>
<td>26.87±5.89</td>
</tr>
<tr>
<td>S-100</td>
<td>ECT</td>
<td>30</td>
<td>30 (100%)</td>
<td>56.32±2.25</td>
</tr>
<tr>
<td>S-100</td>
<td>NET</td>
<td>30</td>
<td>30 (100%)</td>
<td>72.45±2.34</td>
</tr>
</tbody>
</table>

*P<0.05 vs NET group; †P<0.01 vs NET group. ECT: esophageal carcinoma tissue, NET: normal esophageal tissue.

![Figure 3](image-url) Surface phenotype of DCs on d 7 of culture. Flow cytometric analyses of surface molecules in DC generated from PBMNC obtained from a healthy volunteer (A) or an EC patient (B). Representative results of one of the subjects are shown.
Table 3: Expression of CD83 in esophageal tissues

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Prevalence (%)</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECT</td>
<td>30</td>
<td>10 (33.3)</td>
<td>7.82±6.69</td>
</tr>
<tr>
<td>PCT</td>
<td>30</td>
<td>18 (60)</td>
<td>23.34±19.7</td>
</tr>
</tbody>
</table>

*P <0.05 vs PCT group. ECT: esophageal carcinoma tissue, PCT: pericancerous tissue.

Lower expression of S-100 in EC patients

The S100 protein-positive cells were diffusely detected in infiltrating cells of esophageal mucous membrane and epithelium tissues. In ECT, they were localized in cancer cells and cancer nodules; only little could be detected in the tissues away from cancer tissues (Figure 4E, F). Contrast to NET, ECT expressed lower S100-positive cells (*P*<0.05) (Table 2).

Expression of CD83-positive cells

The CD83-positive cells were detected in infiltrating cells in PCT. The NET did not show any positive staining for CD83. In ECT, CD83-positive cells could only be dispersedly detected around cancer nodules, but there were no CD83-positive...
activated DCs in cancer nodules (Figure 5A, B, C). Contrast to PCT, ECT expressed lower CD83-positive cells (P < 0.05) (Table 3).

DISCUSSION

To activate naïve T cells, DCs can uptake, process, and present antigens via their MHC molecules. In addition, T cell activation requires engagement of costimulatory receptors on the T cells. The DCs are at the center of the developing tumor-specific immune response, and are involved both in the initiation of tumor-specific immunity and the generation of immune effector functions. Many observations have suggested that DCs in tumors are functionally impaired[10-24].

In this study, we compared the functions of DCs generated from EC patients with those from healthy volunteers. Our results showed that the allogeneic MLR from EC-DCs was lower than that from N-DCs. With regard to the APC dysfunction in EC-DCs, the decreased expression of costimulators might be involved. Among the examined costimulators, lower expression of CD80 and CD86 was found in EC-DCs. The importance of the CD80/CD86-CD28 system in T cell responses has been well demonstrated[25-28].

The CD80 and CD86, members of the immunoglobulin super gene family, are encoded by separate genes and provide costimulatory function for APC-dependent T-cell activation both in vivo and in vitro[25-28]. A previous study reported that most tumor tissues, like those from the nonhematopoetic origin, did not express costimulatory molecules, which would render T cells unresponsive for the specific antigens[20]. Recent studies demonstrated that B7 expression of tumor cells resulted in increased tumor immunogenicity, enhanced generation of allogeneic and antilognous tumor reactive CTL. The decrease, abrogation or loss of CD80 and CD86 were detected both from EC-DCs and specimens from EC patients in this study, which might have profound implications for the down-regulation of the immune system and for enhancing the progression of esophageal carcinoma.

Furthermore, both the expression of CD80 and CD86 in EC sections could only be detected in the nucleus and cytoplasm but not on the cell membrane, suggesting the impaired transmembrane transduction of CD80 and CD86 molecules. This interesting phenomena was similar to the B7 molecule expression in renal carcinoma and hepatocarcinoma[29,30].

The lower frequency of S100-positive cells in EC indicated the maturation and activation of immature DCs, the decreased expression activated dendritic cells at cancer nodules from patients with EC, including lower amount of DCs, decreased expression of CD80/86, minimally activated DCs, and complete absence of activated DCs in cancer nodules, are correlated to the pathogenesis and progression of EC.

REFERENCES

5. Chen KN, Xu GW. Diagnosis and therapy of esophageal carcinoma. Shijie Huanren Xiaohua Zazhi 2000; 8: 196-202
12. Li MS, Yuan AL. Study about immunology function of dendritic cells from liver patients. Chin Oncology 1998; 6: 85-87
15. Wang YD, Xie W, Qiu YH, Gu ZJ, Zhang XG. The study of dendritic cells induced by cytokines from different adherent cells in vitro. Shanghai Immuno 2000; 20: 140-144

In summary, the impaired immune functions of DCs in patients with EC, including lower amount of DCs, decreased expression of CD80/86, minimally activated DCs, and complete absence of activated DCs in cancer nodules, are correlated to the pathogenesis and progression of EC.
20 Woods GM, Doherty KV, Malley RC, Rist MJ, Muller HK. Carcinogen-modified dendritic cells induce immunosuppression by incomplete T-cell activation resulting from impaired antigen uptake and reduced CD86 expression. *Immunology* 2000; 99: 16-22


*Edited by* Chao JCJ and Xu FM